Aura Biosciences Inc - Asset Resilience Ratio
Aura Biosciences Inc (AURA) has an Asset Resilience Ratio of 21.75% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Aura Biosciences Inc to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Aura Biosciences Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Aura Biosciences Inc asset portfolio.
Liquid Assets Composition Over Time
This chart breaks down Aura Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Aura Biosciences Inc (AURA) financial obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $29.94 Million | 21.75% |
| Total Liquid Assets | $29.94 Million | 21.75% |
Asset Resilience Insights
- Good Liquidity Position: Aura Biosciences Inc maintains a healthy 21.75% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Aura Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Aura Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Aura Biosciences Inc (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Aura Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 50.01% | $84.73 Million | $169.43 Million | -15.42pp |
| 2024-12-31 | 65.42% | $119.40 Million | $182.50 Million | -7.14pp |
| 2023-12-31 | 72.56% | $185.09 Million | $255.07 Million | +42.54pp |
| 2022-12-31 | 30.02% | $67.23 Million | $223.94 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $160.03 Million | -- |
About Aura Biosciences Inc
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the … Read more